NYSE:BIOLife Sciences
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus
Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (NYSE:BIO).
The activist position signals potential pressure for changes in operations, governance, or portfolio structure.
This development comes as Bio-Rad’s shares trade at $281.05 and the company holds a sizable stake in Sartorius.
For investors tracking NYSE:BIO, Elliott’s move lands on top of a mixed share price record, with the stock up 16.3% over the past week and 13.8% over the past year, but down...